



PTO/SB/51 (09-04)
Approved for use through 04/30/2007 OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REISSUE APPLICATION SUPPLEMENTAL DECLARATION BY
THE INVENTOR

Docket Number (Optional)
1662/492021

I hereby declare that:

Each inventor's residence, mailing address and citizenship are stated below next to their name

I believe the inventors named below to be the original and first inventor(s) of the subject matter which is described and claimed in patent number 6,365,574 B2 granted April 2, 2002 and for which a reissue patent is sought on the invention entitled Ethanolate of Azithromycin, Process for Manufacture and Pharmaceutical Compositions Thereof

the specification of which

☐ is attached hereto

☒ was filed on April 2, 2004, reissue application number 10 / 816,376
and was amended on September 27, 2005
(If applicable)

I have reviewed and understand the contents of the above-identified specification including the claims as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56

☐ I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b). Attached is form PTO/SB/02B (or equivalent) listing the foreign applications

I verily believe the original patent to be wholly or partly inoperative or invalid for the reasons described below (Check all boxes that apply)

☐ by reason of a defective specification or drawing

☐ by reason of the patentee claiming more or less than he had the right to claim in the patent

☒ by reason of other errors

At least one error upon which reissue is based is described below. If the reissue is a broadening reissue, such must be stated with an explanation as to the nature of the broadening:

Claims 1, 6 and 7 were amended to recite that the claimed ethanolate of azithromycin is non-hygroscopic to more fully distinguish over US 4,474,768 to Bright which discloses a hygroscopic azithromycin compound



[Page 1 of 2]

This collection of information is required by 37 CFR 1.175. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

NY01 1044301

Best Available Copy

(REISSUE APPLICATION SUPPLEMENTAL DECLARATION BY THE INVENTOR, page 2)		Docket Number (Optional) 1662/492021	
Note: To appoint a power of attorney use form PTO/SB/81 Correspondence Address : Direct all communications about the application to:			
<input checked="" type="checkbox"/> Customer Number : 26646			
OR			
<input type="checkbox"/> Firm or Individual Name			
Address			
City		State	ZIP
Country			
Telephone		Fax	
We hereby declare that every error in the patent which was corrected in the present reissue application and which is not covered by the prior oath(s) and/or declaration(s) submitted in this application arose without any deceptive intention on the part of the applicant			
We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this declaration is directed.			
Full name of sole or first inventor (given name family name) Claude Singer			
Inventor's signature X 		Date X 15.11.05	
Residence 8/8 David Elazar Street, Kfar Saba, Israel 44358		Citizenship Israel	
Mailing Address same as above			
Full name of second joint inventor (given name family name) Judith Aronhime			
Inventor's signature X 		Date X 15.11.05	
Residence Rehov Harav Maor Iosef 5a 76217 Rehovot Israel		Citizenship Israel	
Mailing Address same as above			

[Page 2 of 2]

NY01 1044301

Best Available Copy